MX2019010404A - Compuestos sulfamida cíclicos y métodos de uso de los mismos. - Google Patents

Compuestos sulfamida cíclicos y métodos de uso de los mismos.

Info

Publication number
MX2019010404A
MX2019010404A MX2019010404A MX2019010404A MX2019010404A MX 2019010404 A MX2019010404 A MX 2019010404A MX 2019010404 A MX2019010404 A MX 2019010404A MX 2019010404 A MX2019010404 A MX 2019010404A MX 2019010404 A MX2019010404 A MX 2019010404A
Authority
MX
Mexico
Prior art keywords
methods
same
sulfamide compounds
cyclic sulfamide
hbv
Prior art date
Application number
MX2019010404A
Other languages
English (en)
Inventor
Li Leping
Rai Roopa
Daniel Arnold Lee
Francis Samson
w jr turner William
Nicolas Haydar Simon
G Bures Mark
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of MX2019010404A publication Critical patent/MX2019010404A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos sulfamida cíclicos, y composiciones farmacéuticas con los mismos, que son de utilidad como moduladores de la proteína core de la Hepatitis B (HBV), y también métodos de tratamiento de una infección por Hepatitis B (HBV).
MX2019010404A 2017-03-02 2018-03-01 Compuestos sulfamida cíclicos y métodos de uso de los mismos. MX2019010404A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762465986P 2017-03-02 2017-03-02
US201762529874P 2017-07-07 2017-07-07
US201762549728P 2017-08-24 2017-08-24
PCT/US2018/020515 WO2018160878A1 (en) 2017-03-02 2018-03-01 Cyclic sulfamide compounds and methods of using same

Publications (1)

Publication Number Publication Date
MX2019010404A true MX2019010404A (es) 2019-11-21

Family

ID=61692082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010404A MX2019010404A (es) 2017-03-02 2018-03-01 Compuestos sulfamida cíclicos y métodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US11078170B2 (es)
EP (1) EP3589630B1 (es)
JP (1) JP2020511436A (es)
KR (1) KR20190126102A (es)
CN (1) CN110621672A (es)
AU (1) AU2018227811A1 (es)
BR (1) BR112019018230A2 (es)
CA (1) CA3055194A1 (es)
CL (1) CL2019002503A1 (es)
DO (1) DOP2019000225A (es)
ES (1) ES2898217T3 (es)
IL (1) IL269037A (es)
MX (1) MX2019010404A (es)
PH (1) PH12019502003A1 (es)
SG (1) SG11201908012SA (es)
TW (1) TW201840545A (es)
WO (1) WO2018160878A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053157A1 (en) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
CA3081386A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
TW201925199A (zh) 2017-11-02 2019-07-01 德商艾庫瑞斯公司 對b型肝炎病毒(hbv)具有活性的新穎高活性吡唑并哌啶取代的吲哚-2-甲醯胺
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
US20230075856A1 (en) * 2018-09-05 2023-03-09 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
CN113166086A (zh) * 2018-09-05 2021-07-23 组装生物科学股份有限公司 用于治疗hbv的环状磺酰胺化合物
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
UY38436A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AU2019373679A1 (en) 2018-11-02 2021-05-27 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV)
AU2020265392A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis B virus (HBV)
EP3962909B1 (en) 2019-04-30 2023-10-04 AiCuris GmbH & Co. KG Novel oxalyl piperazines active against the hepatitis b virus (hbv)
CA3138384A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
BR112021021564A2 (pt) 2019-04-30 2022-01-04 Aicuris Gmbh & Co Kg Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv)
CN114761082A (zh) 2019-09-30 2022-07-15 日本化学药品株式会社 氮杂环庚烷衍生物
JP2022554392A (ja) * 2019-11-05 2022-12-28 デルミラ インコーポレイテッド ＭｒｇｐｒＸ２アンタゴニストおよびその使用
WO2021092554A1 (en) * 2019-11-08 2021-05-14 Assembly Biosciences, Inc. Pharmaceutical compositions and methods for treating hbv disorders
WO2021213445A1 (zh) * 2020-04-22 2021-10-28 南京明德新药研发有限公司 内磺酰胺衍生物及其应用
WO2022233305A1 (zh) * 2021-05-07 2022-11-10 南京明德新药研发有限公司 甲基磺酰脲类化合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3223703A (en) * 1963-08-01 1965-12-14 Upjohn Co 3-carbalkoxy- and 3-carbamoyl-5-subtituted - (2h) - 1,2,6 - thiadiazine - 1,1-dioxides and process
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (ja) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピン誘導体
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6927216B2 (en) * 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
DE10109856A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
WO2007047737A1 (en) 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007056388A2 (en) 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
JP4042065B1 (ja) 2006-03-10 2008-02-06 健治 吉田 情報処理装置への入力処理システム
US20100022509A1 (en) 2006-06-07 2010-01-28 Fahey Robert C Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
WO2008045558A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Benzothiadiazine compounds and their use
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
WO2009064852A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
AU2009274255A1 (en) 2008-07-23 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the plasmodial surface anion channel as antimalarials
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
CA2835195A1 (en) * 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP3085368A1 (en) 2011-07-01 2016-10-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US9968650B2 (en) 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
BR112014002845A2 (pt) * 2011-08-19 2017-02-21 Glaxo Group Ltd “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
EP2800742B1 (en) 2012-01-06 2016-04-06 Janssen Sciences Ireland UC 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
BR112015004161B8 (pt) 2012-08-28 2022-11-08 Janssen Sciences Ireland Uc Derivado bicíclico fusionado de sulfamoíla e seu uso no tratamento e prevenção de infecção por vírus da hepatite b, bem como composição farmacêutica e produto que o compreende
UY34993A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
JP6113285B2 (ja) 2012-09-10 2017-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン
RU2015121940A (ru) 2012-11-09 2016-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Альтернативные применения эффекторов сборки вируса гепатита в (hbv)
AU2013355220B2 (en) 2012-12-06 2018-08-02 Baruch S. Blumberg Institute Functionalized benzamide derivatives as antiviral agents against HBV infection
EA201591220A1 (ru) 2012-12-27 2016-01-29 Дрексел Юниверсити Новые противовирусные агенты против инфекции вирусом гепатита в
RU2519546C1 (ru) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
PL2961732T3 (pl) 2013-02-28 2017-09-29 Janssen Sciences Ireland Uc Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
EP2981536B1 (en) 2013-04-03 2017-06-14 Janssen Sciences Ireland UC N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6533217B2 (ja) 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT2997019T (lt) 2013-05-17 2018-11-26 Janssen Sciences Ireland Uc Sulfamoiltiofenamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
KR20160021277A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조절제 및 이의 용도
EP3027612B1 (en) 2013-07-29 2018-10-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
US10183936B2 (en) 2014-03-13 2019-01-22 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
EP3148587B1 (en) * 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
WO2015189035A1 (en) 2014-06-10 2015-12-17 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2018053157A1 (en) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
KR102575605B1 (ko) 2017-03-13 2023-09-05 어셈블리 바이오사이언시스, 인크. B형 간염 코어 단백질 조정제의 제조 방법

Also Published As

Publication number Publication date
WO2018160878A1 (en) 2018-09-07
DOP2019000225A (es) 2019-12-15
US20200157070A1 (en) 2020-05-21
ES2898217T3 (es) 2022-03-04
CN110621672A (zh) 2019-12-27
PH12019502003A1 (en) 2020-06-15
IL269037A (en) 2019-10-31
KR20190126102A (ko) 2019-11-08
CL2019002503A1 (es) 2020-05-15
EP3589630A1 (en) 2020-01-08
EP3589630B1 (en) 2021-07-07
US11078170B2 (en) 2021-08-03
SG11201908012SA (en) 2019-09-27
BR112019018230A2 (pt) 2020-07-21
TW201840545A (zh) 2018-11-16
AU2018227811A1 (en) 2019-09-19
CA3055194A1 (en) 2018-09-07
JP2020511436A (ja) 2020-04-16
US20230012463A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
PH12018500571A1 (en) Hepatitis b core protein modulators
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12021550887A1 (en) 5-membered heteroaryl carboxamide compounds for treatment of hbv
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
PH12021551369A1 (en) Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
PH12017500450A1 (en) Flavivirus virus like particle
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2022002231A (es) Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EA201992054A1 (ru) Циклические сульфамидные соединения и способы их применения
EA201890818A1 (ru) Режим комбинированной терапии для лечения hcv
EA202191634A1 (ru) Замещенные арилметилмочевины и гетероарилметилмочевины, их аналоги и способы их применения
EP3810625A4 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS INFECTION
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида